{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-23-000010","form_type":"8-K","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2023-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.473263+00:00","generated_at":"2026-06-20T20:50:51.222255+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Chemomab CM-101 Phase 2a NASH trial meets safety endpoint; shows positive fibrosis biomarker activity","bullets":["Trial met primary endpoint: safety and tolerability; no significant injection site reactions, no anti-drug antibodies.","23 NASH patients (F1c-F3) received 8 SC doses of 5 mg/kg or placebo over 16 weeks.","CM-101 showed greater improvements vs placebo in fibrosis biomarkers ProC-3, ProC-4, ProC-18, TIMP-1, ELF.","Nearly 60% of CM-101 patients responded in ≥3 fibrosis biomarkers at week 20 vs 0% placebo.","Higher baseline CCL24 correlated with greater biomarker reductions; FibroScan liver stiffness improved vs placebo."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-23-000010","json":"https://secwatch.observer/filing/0001178913-23-000010.json","markdown":"https://secwatch.observer/filing/0001178913-23-000010.md","text":"https://secwatch.observer/filing/0001178913-23-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323000010/0001178913-23-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323000010/zk2328943.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T20:50:51.222255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}